Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy
The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.
Primary Sponsor
The University of Sydney
Collaborating Groups
Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)
Closing Date of Accrual
30 June 2019
Trial Chairperson
A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC
Trial Contact
nivorad@ctc.usyd.edu.au
Related Post
11 June, 2025
Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer
LATEST NEWS: 11 JUNE 2025 New findings from a
10 June, 2025
MRFF $1.5m grant for TROG-sponsored trial of new approach in lung cancer
LATEST NEWS: 10 JUNE 2025 A trial of a
